Enrico Fabris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2135124/publications.pdf

Version: 2024-02-01

69	1,196	17 h-index	32
papers	citations		g-index
69	69	69	1745
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Endomyocardial biopsy in the clinical context: current indications and challenging scenarios. Heart Failure Reviews, 2023, 28, 123-135.	3.9	26
2	Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice. American Journal of Cardiovascular Drugs, 2022, 22, 141-155.	2.2	10
3	COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. Heart, 2022, 108, 458-466.	2.9	28
4	Physical activity in older people: better late than never, but better early than late. Heart, 2022, 108, 328-329.	2.9	4
5	Complementary Pharmacotherapy for STEMI Undergoing Primary PCI: An Evidence-Based Clinical Approach. American Journal of Cardiovascular Drugs, 2022, 22, 463-474.	2.2	2
6	Effect of prehospital treatment in STEMI patients undergoing primary PCI. Catheterization and Cardiovascular Interventions, 2022, 99, 1500-1508.	1.7	9
7	Early prognostic stratification and identification of irreversibly shocked patients despite primary percutaneous coronary intervention. Journal of Cardiovascular Medicine, 2022, 23, 247-253.	1.5	3
8	Thin-Cap Fibroatheroma Rather Than Any Lipid Plaques Increases the Risk of Cardiovascular Events in Diabetic Patients: Insights From the COMBINE OCT–FFR Trial. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS121011728.	3.9	12
9	Evolving concepts in the management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. European Journal of Internal Medicine, 2022, 101, 14-20.	2.2	6
10	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. European Journal of Internal Medicine, 2022, 103, 29-35.	2.2	5
11	Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy. European Journal of Heart Failure, 2021, 23, 657-660.	7.1	O
12	NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial. American Heart Journal, 2021, 233, 78-85.	2.7	7
13	Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. Thrombosis and Haemostasis, 2021, 121, 1562-1573.	3.4	12
14	Prevalence and predictors of persistent sinus rhythm after elective electrical cardioversion for atrial fibrillation. Journal of Cardiovascular Medicine, 2021, 22, 626-630.	1.5	2
15	Variation in treatment strategy for NSTEMI: A complex phenomenon. International Journal of Cardiology, 2021, 331, 14-16.	1.7	1
16	Thin-cap fibroatheroma predicts clinical events in diabeticâ€,patients with normal fractional flow reserve: the COMBINE OCT–FFR trial. European Heart Journal, 2021, 42, 4671-4679.	2.2	121
17	STEMI and Multivessel Disease: Medical Therapy Amplifies the Benefit of Complete Myocardial Revascularisation. Heart Lung and Circulation, 2021, 30, 1846-1853.	0.4	3
18	Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation. European Journal of Heart Failure, 2021, 23, 1765-1774.	7.1	13

#	Article	IF	Citations
19	Intravascular imaging beyond ischaemia assessment: a possible way for improving risk stratification. European Heart Journal Cardiovascular Imaging, 2021, , .	1.2	1
20	Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry. Atherosclerosis, 2021, 332, 48-54.	0.8	28
21	COVID-19 impact on ST-elevation myocardial infarction incidence rate in a Italian STEMI network: a U-shaped curve phenomenon. Journal of Cardiovascular Medicine, 2021, 22, 344-349.	1.5	18
22	Supraventricular Tachycardia Causing Left Ventricular Dysfunction. American Journal of Cardiology, 2021, 159, 72-78.	1.6	3
23	$413\hat{a}{\in}f$ Challenges in the field of cardiac tumours: the surgical experience of Trieste. European Heart Journal Supplements, 2021, 23, .	0.1	0
24	350â€∫Effect of pre-hospital treatment for STEMI patients undergoing primary PCI. European Heart Journal Supplements, 2021, 23, .	0.1	0
25	Gender-related differences in heart failure: beyond the "one-size-fits-all―paradigm. Heart Failure Reviews, 2020, 25, 245-255.	3.9	35
26	Sex Differences in the Long-term Prognosis of Dilated Cardiomyopathy. Canadian Journal of Cardiology, 2020, 36, 37-44.	1.7	48
27	Resolute zotarolimusâ€eluting stent in STâ€elevation myocardial infarction (resoluteâ€6TEMI): A prespecified prospective register from the DAPTâ€6TEMI trial. Catheterization and Cardiovascular Interventions, 2020, 95, 706-710.	1.7	2
28	Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention. Current Atherosclerosis Reports, 2020, 22, 76.	4.8	4
29	Cardiac Tumors: Diagnosis, Prognosis, and Treatment. Current Cardiology Reports, 2020, 22, 169.	2.9	84
30	Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. Journal of the American College of Cardiology, 2020, 76, 2321-2330.	2.8	154
31	Accuracy of right atrial pressure estimation using a multi-parameter approach derived from inferior vena cava semi-automated edge-tracking echocardiography: a pilot study in patients with cardiovascular disorders. International Journal of Cardiovascular Imaging, 2020, 36, 1213-1225.	1.5	14
32	Intravascular Imaging Guidance of LeftÂMain PCI. JACC: Cardiovascular Interventions, 2020, 13, 358-360.	2.9	1
33	Hat-Marker Orientation to Minimize Neo-Commissural Overlap With Coronaries During CoreValve Evolut TAVR. JACC: Cardiovascular Interventions, 2020, 13, 782-783.	2.9	3
34	Impact of patient delay in a modern real world STEMI network. American Journal of Emergency Medicine, 2020, 38, 1195-1198.	1.6	13
35	Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. Cardiovascular Diabetology, 2020, 19, 215.	6.8	30
36	Beta-blocker effect on ST-segment: a prespecified analysis of the EARLY-BAMI randomised trial. Open Heart, 2020, 7, .	2.3	0

#	Article	IF	CITATIONS
37	Beta-blocker effect on ST-segment: a prespecified analysis of the EARLY-BAMI randomised trial. Open Heart, 2020, 7, e001316.	2.3	1
38	Impact of ambulatory cardiac rehabilitation on cardiovascular outcomes: a long-term follow-up study. European Heart Journal, 2019, 40, 678-685.	2.2	58
39	Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach. Drugs, 2019, 79, 1543-1556.	10.9	11
40	Prognostic Role of Left Ventricular Dysfunction in Patients With Coronary Artery Disease After an Ambulatory Cardiac Rehabilitation Program. American Journal of Cardiology, 2019, 124, 355-361.	1.6	5
41	Appropriateness, inappropriateness and waste of resources: Unfulfilled expectations?. European Journal of Internal Medicine, 2019, 63, 15-18.	2.2	3
42	Treatment of Functional Mitral Regurgitation in Heart Failure. Current Cardiology Reports, 2019, 21, 139.	2.9	1
43	Effect of early tirofiban administration on Nâ€terminal proâ€Bâ€type natriuretic peptide level in patients treated with primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2019, 93, E293-E297.	1.7	3
44	Preâ€hospital administration of ticagrelor in diabetic patients with STâ€elevation myocardial infarction undergoing primary angioplasty: A subâ€analysis of the ATLANTIC trial. Catheterization and Cardiovascular Interventions, 2019, 93, E369-E377.	1.7	4
45	Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 208-217.	1.0	17
46	Entrapment of dissection flap and intimal tissue cleavage during rotational atherectomy. Cardiovascular Intervention and Therapeutics, 2019, 34, 178-179.	2.3	0
47	Inflammation in cardiac amyloidosis: prognostic marker or therapeutic target?. European Journal of Heart Failure, 2018, 20, 758-759.	7.1	2
48	Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ: British Medical Journal, 2018, 363, k3793.	2.3	125
49	Early occurrence of drug intolerance as risk factor during follow-up in patients with acute coronary syndrome or coronary revascularization. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 195-201.	3.0	7
50	One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction. JAMA Cardiology, 2017, 2, 791.	6.1	17
51	A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial― American Heart Journal, 2017, 188, 11-17.	2.7	13
52	International Subspecialty FellowshipÂTraining, the Path forÂCardiologists of Tomorrow?. Journal of the American College of Cardiology, 2017, 69, 1200-1203.	2.8	5
53	The evolution of cardiology: changes, future challenges and opportunities. Future Cardiology, 2017, 13, 161-171.	1.2	4
54	Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction. Heart, 2017, 103, 1515-1520.	2.9	19

#	Article	IF	CITATIONS
55	Is ischemia the only factor predicting cardiovascular outcomes in all diabetes mellitus patients?. Cardiovascular Diabetology, 2017, 16, 51.	6.8	22
56	Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. EuroIntervention, 2017, 13, 69-77.	3.2	18
57	Bioresorbable vascular scaffold restenosis. Journal of Cardiovascular Medicine, 2016, 17, e132-e135.	1.5	1
58	Combined optical coherence tomography morphologic and fractional flow reserve hemodynamic assessment of non- culprit lesions to better predict adverse event outcomes in diabetes mellitus patients: COMBINE (OCT–FFR) prospective study. Rationale and design. Cardiovascular Diabetology, 2016, 15, 144.	6.8	34
59	Direct cellular reprogramming: the hopes and the hurdles. European Journal of Heart Failure, 2016, 18, 157-159.	7.1	4
60	Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus. Cardiovascular Diabetology, 2016, 15, 100.	6.8	35
61	Fractional Flow Reserve–Guided Deferred Versus Complete Revascularization in Patients With Diabetes Mellitus. American Journal of Cardiology, 2016, 118, 1293-1299.	1.6	17
62	Nonatherosclerotic Coronary Artery Narrowing. JACC: Cardiovascular Imaging, 2016, 9, 317-320.	5.3	6
63	Bilateral coronary obstruction in high-risk transcatheter aortic valve-in-valve implantation: When procedural strategy counts. International Journal of Cardiology, 2016, 203, 672-674.	1.7	5
64	Near-infrared spectroscopy-intravascular ultrasound: scientific basis and clinical applications. European Heart Journal Cardiovascular Imaging, 2015, 16, jev208.	1.2	31
65	Three-vessel coronary artery disease evaluation by multimodality imaging with near-infrared spectroscopy (NIRS) plus intravascular ultrasound (IVUS) and optical coherence tomography (OCT). International Journal of Cardiology, 2015, 180, 21-29.	1.7	2
66	Calcific degeneration and rupture of the aortic valve and ascending aorta: from cardiac auscultation to multimodality imaging. Journal of Geriatric Cardiology, 2015, 12, 580-3.	0.2	1
67	Prognostic Significance of Atrial Fibrillation and Severity of Symptoms of Heart Failure in Patients With Low Gradient Aortic Stenosis and Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology, 2014, 114, 1722-1728.	1.6	21
68	Influence of multimodality coronary imaging on revascularization strategy. International Journal of Cardiology, 2014, 177, 515-516.	1.7	1
69	Uncommon cause of ST-segment elevation in V1–V3: incremental value of cardiac magnetic resonance imaging. Clinical Research in Cardiology, 2014, 103, 825-828.	3.3	1